TRU Truscreen Group Ltd
- 0.019
- 0.0000.00%
Truscreen Group Ltd News
Truscreen Group Raises Additional NZ$520,000 via Share Placement; Shares Jump 5%
Truscreen Group (ASX:TRU, NZE:TRU) obtained an additional firm commitment from an investor for the placement of 26 million shares at NZ$0.02 each, resulting in a total raise of NZ$520,000, excluding e
New Zealand Shares Jump on Friday, Fisher & Paykel Healthcare's Chair to Retire
New Zealand shares jumped on Friday's close, tracking their global counterparts, as investors cheered US Federal Reserve Chair Jerome Powell's pronouncements that rate cuts may start within the year.
TruScreen to Start Clinical Evaluation Trials for Cancer Screening Device
TruScreen (NZE:TRU, ASX:TRU) is set to start clinical evaluation trials in Kenya and Indonesia for its TruScreen cervical cancer device, according to a filing with the New Zealand Stock Exchange on Fr
Truscreen Close to Raising NZ$500,000
Truscreen Group (ASX:TRU) has secured firm commitments for the sale of 25 million shares at NZ$0.02 apiece, to raise NZ$500,000. Those shares will be issued under the medical device maker's existing 1
New Zealand Shares Close the Week in the Green; Port of Tauranga's Fiscal H1 Revenue Falls
New Zealand shares inched up on Friday's close after a volatile trading week as investors turned their attention to the Reserve Bank of New Zealand's upcoming policy meeting. The S&P/NZX 50 rose 0.25%
Truscreen Group to Offer Pro-Rata Renounceable Rights Issue; Shares Plunge 11%
Truscreen Group (ASX:TRU, NZE:TRU) plans to launch a one-for-three pro-rata renounceable rights issue to raise up to NZ$2.8 million, the medical device firm said on Monday. The rights offer price stan
TruScreen Secures Reimbursement Approval in Saudi Arabia for Cervical Cancer Screening Device; Shares Rise 4%
TruScreen's (NZE:TRU) distributor, Bettalife, secured reimbursement approvals from most Saudi Arabian insurers for its cervical cancer screening device TruScreen, the medical device firm said on Monda
Truscreen Secures Regulatory Approval to Expand Use of Cancer Screening Device in Mexico; Shares Rise 4%
Truscreen (NZE:TRU, ASX:TRU) secured regulatory approval from Mexican regulator Cofepris to expand the use of its cervical cancer screening device, TruScreen, to the country's public health sector. Th
TruScreen's Nine-Month Revenue Surges 34%
TruScreen (NZE:TRU, ASX:TRU) reported a 40% year-over-year growth in sales of devices and a 22% year-on-year growth in sales of single disposable sensors (SUSs) for the nine months through December 20
New Zealand Bourse Regulator Slaps TruScreen a Fine on Audit Committee Breach
The New Zealand Markets Disciplinary Tribunal imposed on Truscreen (NZE:TRU, ASX:TRU) a NZ$25,000 fine related to the insufficient number of members in its audit committee from Oct 2020 to August 2023
TruScreen Wins Polish Start-Up Challenge; Shares Rise 5%
TruScreen (NZE:TRU, ASX:TRU) secured the top prize from a seven-month startup challenge organized by the Mother and Child Institute in Poland for its TruScreen cervical cancer screening technology. Th
New Zealand Shares Rebound on Wednesday, Air New Zealand Expects Fiscal H1 Earnings to Be on the Lower End of Guidance
New Zealand shares rebounded on Wednesday's close following a two-day losing streak as investors placed their bets on the next US Federal Reserve meeting. The S&P/NZ50 Index rose 0.79% or 90.49 points
TruScreen's Diagnostic Device Lands Spot in Vietnam Health Ministry's Approved Technical List; Shares Rise 5%
TruScreen's (NZE:TRU, ASX:TRU) cervical cancer diagnostic device, TruScreen Ultra, secured a spot in the approved technical list of Vietnam's Ministry of Health. The listing will help expedite the pro
TruScreen Secures Purchase Order From Zimbabwe
TruScreen Group (ASX:TRU, NZE:TRU) received a NZ$300,000 purchase order for a single use sensor from Zimbabwe. The single use sensor is the disposal consumable item used in each TruScreen cervical can
Truscreen Logs 33% Growth in Fiscal H1 Revenue
Truscreen Group (ASX:TRU) logged a 33% year-over-year growth in revenue in the first half of the 2024 financial year, at AU$986,051, from AU$740,034 in the corresponding period of the preceding fiscal
Middle Eastern Hospital Network Adopts TruSreen's Cervical Cancer Screening Device in Saudi Arabia
TruScreen (ASX:TRU) on Monday said that following an initial evaluation phase, the private hospital network of Dr Sulaiman Al-Habib Medical Group has installed four TruScreen devices for the commercia
TruScreen Technology Recognized in China Cervical Cancer Screening Guideline
Medical device company Truscreen Group's (ASX:TRU) technology was acknowledged in the China Cervical Cancer Screening Guideline published by the Chinese Society for Colposcopy and Cervical Pathology (
TruScreen Group (ASX:TRU) Launches Rights Offer of NZD$2.2 Million
Analysis
Price Target
No Data
